Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Neurocrine Biosciences, Inc. - Common Stock
(NQ:
NBIX
)
136.63
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurocrine Biosciences, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
4 Analysts Have This to Say About Neurocrine Biosciences
September 26, 2022
Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022
September 26, 2022
Upgrades
Via
Benzinga
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
September 24, 2022
Eli Lilly leads medical stocks setting up and showing relative strength.
Via
Investor's Business Daily
Neurocrine Biosciences Buys UK-Based Hormone Therapy Player
August 30, 2022
Via
Benzinga
Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance
August 05, 2022
Via
Benzinga
S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms
September 17, 2022
Devon Energy leads this weekend's watch list of stocks in a tough market.
Via
Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Neurocrine Leads 5 Stocks To Watch In Sickly Market
September 03, 2022
Neurocrine Biosciences leads five medical stocks showing resilience.
Via
Investor's Business Daily
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Neurocrine Biosciences Shelves Key Drug; Will It Overshadow The Earnings Beat?
August 04, 2022
Neurocrine says the essential tremor drug didn't hit its goals in a key study.
Via
Investor's Business Daily
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
August 05, 2022
The Nasdaq and small caps rose while the S&P 500 is hitting resistance.
Via
Investor's Business Daily
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Dow Jones Giant Amgen Leads 5 Stocks To Watch Near Buy Points
July 23, 2022
Dow Jones giant Amgen headlines five stocks to watch setting near buy points or key support levels that may offer early entries.
Via
Investor's Business Daily
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
July 11, 2022
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.
Via
Benzinga
Neurocrine Biosciences Earnings Perspective: Return On Capital Employed
May 19, 2022
According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60...
Via
Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
May 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Neurocrine Biosciences: Q1 Earnings Insights
May 04, 2022
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET
April 25, 2022
Neurocrine Biosciences (NASDAQ:NBIX) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
What 8 Analyst Ratings Have To Say About Neurocrine Biosciences
April 04, 2022
Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
March 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
March 03, 2022
Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,...
Via
Benzinga
Where Neurocrine Biosciences Stands With Analysts
February 25, 2022
Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022
February 25, 2022
Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56,...
Via
Benzinga
Looking Into Neurocrine Biosciences's Return On Capital Employed
February 14, 2022
Benzinga Pro data, Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 sales of $312.00 million. Earnings fell to a loss of $7.30 million, resulting in a 132.44% decrease from last quarter.
Via
Benzinga
Why Neurocrine Biosciences Are Trading Higher Today?
February 11, 2022
Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million...
Via
Benzinga
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
February 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-...
Via
Benzinga
Recap: Neurocrine Biosciences Q4 Earnings
February 11, 2022
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q4 earnings results on Friday, February 11, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Neurocrine...
Via
Benzinga
Earnings Scheduled For February 11, 2022
February 11, 2022
Companies Reporting Before The Bell • Mr. Cooper Group (NASDAQ:COOP) is expected to report quarterly earnings at $1.22 per share on revenue of $551.60 million.
Via
Benzinga
A Preview Of Neurocrine Biosciences's Earnings
February 10, 2022
Neurocrine Biosciences (NASDAQ:NBIX) is set to give its latest quarterly earnings report on Friday, 2022-02-11. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.